Ποια είναι η τιμή για Bellicum Pharmaceuticals, Inc. (BLCM)

Η τιμή για Bellicum Pharmaceuticals, Inc. (BLCM) είναι $0.07475

Ποια είναι η κεφαλαιοποίηση αγοράς για Bellicum Pharmaceuticals, Inc. (BLCM)

Η κεφαλαιοποίηση αγοράς για Bellicum Pharmaceuticals, Inc. (BLCM) είναι $755.60K

Bellicum Pharmaceuticals, Inc. (BLCM) Τιμή και Κεφαλαιοποίηση Αγοράς

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

Η τιμή για BLCM	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$541,885 $755.60K	NVDA	$5.478T	+724,929,046.33%
$444,011 $755.60K	AAPL	$4.488T	+593,994,561.20%
$411,882 $755.60K	GOOG	$4.163T	+551,012,739.79%
$366,474 $755.60K	MSFT	$3.704T	+490,265,723.71%
$281,102 $755.60K	AMZN	$2.841T	+376,056,071.60%

Η τιμή για BLCM

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$541,885 $755.60K